WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

WMT

120.8

+1.54%↑

COST

966.71

-0.51%↓

PG

144.02

-0.41%↓

KO

75.18

+0.55%↑

PM

163.47

+0.29%↑

Search

Lifecore Biomedical Inc

Geschlossen

BrancheKonsumgüter defensiv

4.03 0.5

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.85

Max

4.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.9M

-10M

Verkäufe

-5.3M

31M

Gewinnspanne

-32.116

Angestellte

406

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+61.69% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

10. Juni 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-21M

220M

Vorheriger Eröffnungskurs

3.53

Vorheriger Schlusskurs

4.03

Nachrichtenstimmung

By Acuity

72%

28%

112 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. März 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. März 2026, 22:55 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. März 2026, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. März 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. März 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. März 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. März 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. März 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. März 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. März 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. März 2026, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. März 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. März 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. März 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. März 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. März 2026, 21:10 UTC

Wichtige Nachrichtenereignisse

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. März 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk
Ergebnisse
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Kursziel

By TipRanks

61.69% Vorteil

12-Monats-Prognose

Durchschnitt 6.5 USD  61.69%

Hoch 9 USD

Tief 5 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lifecore Biomedical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Stimmung

By Acuity

112 / 131 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat